Market Summary
USD8.94-0.06
Market Closed-0.67%
PACB Stock Price
PACB RSI Chart
PACB Valuation
PACB Price/Sales (Trailing)
PACB Profitability
PACB Fundamentals
PACB Revenue
PACB Earnings
Price Action
52 Week Range
4.9714.55
(Low)(High)
Last 7 days
-14.2%
Last 30 days
-14.8%
Last 90 days
-28.5%
Trailing 12 Months
65.3%
PACB Financial Health
PACB Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for PACB
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-18 | HENRY CHRISTIAN O | sold | -980,255 | 10.122 | -96,844 | see remarks |
2023-09-11 | HENRY CHRISTIAN O | sold | -104,520 | 10.452 | -10,000 | see remarks |
2023-08-17 | Eidel Jeff | sold | -274,844 | 10.597 | -25,936 | see remarks |
2023-08-17 | HENRY CHRISTIAN O | sold | -105,000 | 10.5 | -10,000 | see remarks |
2023-08-16 | Van Oene Mark | sold | -287,122 | 11.00 | -26,102 | see remarks |
2023-05-18 | Farmer Michele | sold | -65,027 | 12.59 | -5,165 | see remarks |
2023-05-18 | MOHR MARSHALL | acquired | 63,500 | 2.54 | 25,000 | - |
2023-03-15 | Ericson William W. | sold | -67,114 | 8.9 | -7,541 | - |
2023-03-15 | Ericson William W. | acquired | 63,500 | 2.54 | 25,000 | - |
2023-03-03 | Farmer Michele | sold | -29,931 | 9.493 | -3,153 | see remarks |
Which funds bought or sold PACB recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | reduced | -40.00 | -46,850 | 174,150 | -% |
2023-09-20 | BARCLAYS PLC | added | 100 | 2,344,000 | 4,141,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | reduced | -55.12 | -10,953 | 11,651 | -% |
2023-09-06 | Deep Track Capital, LP | reduced | -58.59 | -21,279,900 | 19,301,000 | 0.89% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 101 | 212,940 | 375,060 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -2.75 | 56,966 | 539,739 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 4.21 | 640,297 | 3,892,640 | -% |
2023-08-16 | Neo Ivy Capital Management | new | - | 802,000 | 802,000 | 0.42% |
2023-08-16 | GTS SECURITIES LLC | new | - | 2,763,730 | 2,763,730 | 0.09% |
2023-08-16 | Nuveen Asset Management, LLC | added | 0.8 | 1,201,290 | 8,818,290 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Pacific Biosciences of California
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital international investors | 2.7% | 6,099,681 | SC 13G/A | |
| Feb 13, 2023 | madrone capital partners, llc | 7.3% | 16,415,933 | SC 13G/A | |
| Feb 10, 2023 | nikko asset management americas, inc. | 6.26% | 14,166,193 | SC 13G/A | |
| Feb 10, 2023 | ark investment management llc | 11.36% | 25,691,681 | SC 13G/A | |
| Feb 10, 2023 | jackson square partners, llc | 6.64% | 15,005,177 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.97% | 20,279,035 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.2% | 18,534,459 | SC 13G/A | |
| Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 6.26% | 14,166,193 | SC 13G/A | |
| Jun 01, 2022 | madrone capital partners, llc | 6.0% | 13,415,933 | SC 13G | |
| Feb 14, 2022 | nikko asset management americas, inc. | 5.40% | 11,915,025 | SC 13G |
Recent SEC filings of Pacific Biosciences of California
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 22, 2023 | 8-K/A | Current Report | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 18, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Aug 18, 2023 | 4 | Insider Trading | |
| Aug 18, 2023 | 4 | Insider Trading | |
| Aug 18, 2023 | 4 | Insider Trading | |
| Aug 18, 2023 | 144/A | 144/A | |
| Aug 17, 2023 | D | D | |
| Aug 17, 2023 | 144 | Notice of Insider Sale Intent |
Peers (Alternatives to Pacific Biosciences of California)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 32.6B | 7.0B | -6.48% | -10.43% | 28.81 | 4.67 | 5.03% | -14.68% |
MTD | 24.1B | 4.0B | -5.58% | -3.13% | 27.06 | 6.08 | 2.30% | 16.37% |
ILMN | 20.9B | 4.5B | -19.21% | -31.55% | -5 | 4.69 | -4.92% | -21931.58% |
PKI | 16.1B | 2.8B | -15.95% | -22.45% | 19.74 | 5.69 | -24.31% | 21.35% |
WAT | 15.9B | 3.0B | -0.75% | -2.22% | 23.55 | 5.31 | 3.16% | -3.93% |
| MID-CAP | ||||||||
| SMALL-CAP | ||||||||
PACB | 2.2B | 146.1M | -14.78% | 65.25% | -7.02 | 15.32 | 4.72% | -55.19% |
QTRX | 939.5M | 112.0M | 0.16% | 189.80% | -14.28 | 8.39 | 0.83% | 16.42% |
ADPT | 733.4M | 189.6M | -22.00% | -26.52% | -3.84 | 3.87 | 18.74% | 17.75% |
HBIO | 174.6M | 114.1M | -3.08% | 57.31% | -32.16 | 1.53 | -5.49% | -48.58% |
CDXS | 108.9M | 99.2M | -12.85% | -74.80% | -1.92 | 1.1 | -26.56% | -199.52% |
BNGO | 97.1M | 31.5M | -3.63% | 53.68% | -0.66 | 3.08 | 35.12% | -38.47% |
CSBR | 72.8M | 52.7M | -15.89% | -34.39% | -9.64 | 1.38 | 2.10% | -1984.29% |
NSTG | 71.3M | 143.9M | -47.74% | -88.57% | -0.43 | 0.5 | 0.71% | -18.99% |
PSNL | 60.1M | 67.1M | -27.06% | -59.74% | -0.55 | 0.9 | -12.13% | -17.68% |
Pacific Biosciences of California News
Returns for PACB
Cumulative Returns on PACB
10.0%
10-Year Cumulative Returns
-0.3%
7-Year Cumulative Returns
13.2%
5-Year Cumulative Returns
0.6%
3-Year Cumulative Returns
Risks for PACB
What is the probability of a big loss on PACB?
100%
Probability that Pacific Biosciences of California stock will be more than 20% underwater in next one year
87.7%
Probability that Pacific Biosciences of California stock will be more than 30% underwater in next one year.
69.6%
Probability that Pacific Biosciences of California stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does PACB drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Pacific Biosciences of California was unfortunately bought at previous high price.
Drawdowns
Financials for Pacific Biosciences of California
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 9.0% | 146,137,000 | 134,031,000 | 128,304,000 | 136,970,000 | 139,546,000 | 134,689,000 | 130,513,000 | 121,630,000 | 105,825,000 | 92,292,000 | 78,893,000 | 79,687,000 | 82,520,000 | 90,064,000 | 90,891,000 | 82,487,000 | 78,732,000 | 75,689,000 | 78,626,000 | 84,035,000 | 89,420,000 |
| Cost Of Revenue | 14.3% | 102,143,000 | 89,390,000 | 79,269,000 | 76,309,000 | 77,068,000 | 74,651,000 | 71,653,000 | 69,866,667 | 65,754,000 | 64,080,000 | 46,327,000 | - | - | - | 56,315,000 | - | - | - | - | - | - |
| Gross Profit | -1.4% | 43,994,000 | 44,641,000 | 49,035,000 | 60,661,000 | 62,478,000 | 60,038,000 | 58,860,000 | 53,495,000 | 45,195,000 | 38,055,000 | 32,566,000 | 34,097,000 | 33,947,000 | 36,947,000 | 34,576,000 | 27,390,000 | 23,668,000 | 22,917,000 | 25,096,000 | 28,844,000 | 33,879,000 |
| Operating Expenses | 1.2% | 370,125,000 | 365,566,000 | 356,231,000 | 345,449,000 | 347,122,000 | 314,286,000 | 269,295,000 | 223,231,000 | 164,630,000 | 143,441,000 | 136,951,000 | 132,422,000 | 136,211,000 | 140,067,000 | 135,121,000 | 140,641,000 | 133,475,000 | 130,089,000 | 126,083,000 | 119,737,000 | 121,671,000 |
| S&GA Expenses | 0.8% | 162,189,000 | 160,868,000 | 160,854,000 | 153,171,000 | 147,982,000 | 137,790,000 | 124,124,000 | 104,758,000 | 87,924,000 | 73,991,000 | 72,799,000 | 71,422,000 | 76,716,000 | 80,672,000 | 75,491,000 | 79,021,000 | 72,461,000 | 68,321,000 | 63,489,000 | 57,780,000 | 58,226,000 |
| R&D Expenses | -2.2% | 184,827,000 | 189,002,000 | 193,000,000 | 192,953,000 | 173,369,000 | 145,287,000 | 112,899,000 | 87,747,000 | 76,706,000 | 69,450,000 | 64,152,000 | 61,000,000 | 59,495,000 | 59,395,000 | 59,630,000 | 61,620,000 | 61,014,000 | 61,768,000 | 62,594,000 | 61,957,000 | 63,445,000 |
| EBITDA | 100.0% | - | -307,903,333 | -290,078,000 | -266,535,000 | - | -252,572,000 | -255,142,000 | 8,873,000 | - | 38,407,000 | 36,885,000 | -86,672,000 | -75,310,000 | -74,666,000 | -74,308,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -2.30 | -2.26 | -1.95 | - | -1.88 | -1.95 | 0.07 | - | 0.42 | 0.47 | -1.09 | -0.91 | -0.83 | -0.82 | - | - | - | - | - | - |
| Interest Expenses | -0.9% | 14,496,000 | 14,623,000 | 14,690,000 | 14,521,000 | 14,530,000 | 14,438,000 | 12,530,000 | 9,051,000 | 5,378,000 | 1,789,000 | 267,000 | 945,000 | 1,609,000 | 2,253,000 | 2,611,000 | 2,561,000 | 2,513,000 | 2,467,000 | 2,423,000 | 2,419,000 | 2,436,000 |
| Earnings Before Taxes | 0.5% | -319,203,000 | -320,764,000 | -314,248,000 | -298,018,000 | -299,329,000 | -303,913,333 | -274,872,000 | -6,694,000 | - | - | 29,403,000 | -94,832,000 | - | - | -84,134,000 | - | - | - | - | - | - |
| EBT Margin | 100.0% | - | -2.48 | -2.45 | -2.12 | - | -2.04 | -2.11 | -0.06 | - | 0.32 | 0.37 | -1.19 | -1.02 | -0.93 | -0.93 | - | - | - | - | - | - |
| Net Income | 0.5% | -319,203,000 | -320,764,000 | -314,248,000 | -299,193,000 | -205,680,000 | -175,287,000 | -181,223,000 | -36,959,000 | -77,209,000 | -59,294,000 | 29,403,000 | -45,623,000 | -51,038,000 | -52,548,000 | -84,134,000 | -114,842,000 | -110,763,000 | -108,707,000 | -102,562,000 | -92,525,000 | -89,502,000 |
| Net Income Margin | 100.0% | - | -2.39 | -2.45 | -2.18 | -1.47 | -1.30 | -1.39 | -0.30 | -0.73 | -0.64 | 0.37 | -0.57 | -0.62 | -0.58 | -0.93 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -295,706,000 | -279,961,000 | -249,041,000 | -223,574,000 | -176,273,000 | -117,111,000 | -96,891,000 | -73,460,000 | -80,287,000 | 18,464,000 | 14,473,000 | 14,728,000 | 20,664,000 | -81,148,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -2.6% | 1,848 | 1,896 | 1,767 | 1,819 | 1,876 | 1,937 | 2,007 | 2,034 | 1,246 | 1,253 | 414 | 300 | 214 | 235 | 148 | 146 | 171 | 186 | 170 | 183 | 137 |
| Current Assets | -4.6% | 936 | 981 | 852 | 914 | 970 | 1,029 | 1,101 | 1,130 | 1,189 | 1,196 | 356 | 240 | 151 | 170 | 81.00 | 77.00 | 99.00 | 113 | 132 | 144 | 96.00 |
| Cash Equivalents | -40.9% | 209 | 354 | 325 | 304 | 310 | 429 | 466 | 425 | 460 | 932 | 82.00 | 69.00 | 43.00 | 69.00 | 34.00 | 33.00 | 30.00 | 38.00 | 34.00 | 38.00 | 23.00 |
| Inventory | 9.1% | 68.00 | 62.00 | 50.00 | 43.00 | 36.00 | 30.00 | 25.00 | 18.00 | 18.00 | 16.00 | 14.00 | 16.00 | 17.00 | 16.00 | 13.00 | 15.00 | 17.00 | 20.00 | 18.00 | 20.00 | 23.00 |
| Net PPE | -1.3% | 40.00 | 41.00 | 42.00 | 39.00 | 38.00 | 36.00 | 33.00 | 31.00 | 25.00 | 24.00 | 25.00 | 27.00 | 28.00 | 29.00 | 30.00 | 32.00 | 33.00 | 34.00 | 34.00 | 34.00 | 36.00 |
| Goodwill | 0% | 410 | 410 | 410 | 410 | 410 | 410 | 410 | 391 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Liabilities | 0.1% | 1,206 | 1,204 | 1,204 | 1,192 | 1,194 | 1,202 | 1,216 | 1,193 | 988 | 972 | 78.00 | 171 | 172 | 174 | 93.00 | 95.00 | 95.00 | 91.00 | 56.00 | 51.00 | 52.00 |
| Current Liabilities | 2.2% | 271 | 266 | 263 | 82.00 | 84.00 | 61.00 | 72.00 | 56.00 | 45.00 | 34.00 | 39.00 | 130 | 131 | 132 | 49.00 | 51.00 | 49.00 | 45.00 | 27.00 | 22.00 | 22.00 |
| Shareholder's Equity | -7.2% | 642 | 692 | 563 | 627 | 682 | 735 | 791 | 841 | 258 | 281 | 335 | 129 | 41.00 | 60.00 | 55.00 | 51.00 | 76.00 | 95.00 | 114 | 132 | 85.00 |
| Retained Earnings | -4.3% | -1,690 | -1,620 | -1,532 | -1,447 | -1,370 | -1,299 | -1,218 | -1,148 | -1,165 | -1,124 | -1,036 | -1,111 | -1,088 | -1,065 | -1,066 | -1,066 | -1,037 | -1,012 | -982 | -951 | -926 |
| Additional Paid-In Capital | 0.9% | 2,335 | 2,314 | 2,100 | 2,081 | 2,058 | 2,038 | 2,010 | 1,989 | 1,423 | 1,405 | 1,372 | 1,241 | 1,129 | 1,125 | 1,121 | 1,117 | 1,113 | 1,107 | 1,096 | 1,083 | 1,012 |
| Shares Outstanding | 0.3% | 250 | 250 | 227 | 226 | 224 | 222 | 221 | 202 | 199 | 195 | 192 | 167 | 154 | 153 | 153 | 153 | 153 | 151 | 150 | 149 | 132 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 6.7% | -260 | -278 | -263 | -234 | -211 | -167 | -111 | -93.73 | -70.89 | -78.96 | 20.00 | 16.00 | 16.00 | 22.00 | -78.31 | -79.12 | -76.03 | -72.97 | -66.43 | -67.64 | -71.31 |
| Share Based Compensation | -1.5% | 73.00 | 74.00 | 79.00 | 80.00 | 89.00 | 86.00 | 73.00 | 60.00 | 36.00 | 24.00 | 18.00 | 16.00 | 15.00 | 16.00 | 16.00 | 20.00 | 21.00 | 22.00 | 23.00 | 21.00 | 21.00 |
| Cashflow From Investing | -2593.8% | -36.83 | 1.00 | 116 | 101 | -244 | -644 | -678 | -842 | -614 | -156 | -219 | -124 | -40.93 | -30.26 | 62.00 | 60.00 | 3.00 | 7.00 | -38.41 | -22.22 | 20.00 |
| Cashflow From Financing | -2.6% | 195 | 200 | 10.00 | 10.00 | 307 | 309 | 1,170 | 1,294 | 1,102 | 1,099 | 252 | 144 | 37.00 | 38.00 | 27.00 | 14.00 | 80.00 | 78.00 | 107 | 102 | 38.00 |
PACB Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Total revenue | $ 47,573 | $ 35,467 | $ 86,473 | $ 68,640 |
| Cost of Revenue: | ||||
| Amortization of intangible assets | 183 | 183 | 366 | 366 |
| Total cost of revenue | 32,027 | 19,274 | 61,166 | 38,292 |
| Gross profit | 15,546 | 16,193 | 25,307 | 30,348 |
| Operating Expense: | ||||
| Research and development | 46,173 | 50,348 | 95,112 | 103,285 |
| Sales, general and administrative | 40,573 | 39,252 | 80,391 | 79,056 |
| Change in fair value of contingent consideration | 1,975 | (5,438) | 14,231 | (6,501) |
| Total operating expense | 88,721 | 84,162 | 189,734 | 175,840 |
| Operating loss | (73,175) | (67,969) | (164,427) | (145,492) |
| Loss on extinguishment of debt | (2,033) | 0 | (2,033) | 0 |
| Interest expense | (3,554) | (3,681) | (7,184) | (7,378) |
| Other income (expense), net | 8,929 | 256 | 15,796 | (23) |
| Loss before expense (benefit) from income taxes | (69,833) | (71,394) | (157,848) | (152,893) |
| Expense (benefit) from income taxes | 0 | 0 | 0 | 0 |
| Net loss | (69,833) | (71,394) | (157,848) | (152,893) |
| Other comprehensive (loss) income: | ||||
| Unrealized (loss) gain on investments | (762) | (1,372) | 2,079 | (4,370) |
| Comprehensive loss | $ (70,595) | $ (72,766) | $ (155,769) | $ (157,263) |
| Net loss per share: | ||||
| Basic (in dollars per share) | $ (0.28) | $ (0.32) | $ (0.64) | $ (0.68) |
| Diluted (in dollars per share) | $ (0.28) | $ (0.32) | $ (0.64) | $ (0.68) |
| Weighted average shares outstanding used in calculating net loss per share: | ||||
| Basic (in shares) | 250,070 | 224,499 | 246,074 | 223,400 |
| Diluted (in shares) | 250,070 | 224,499 | 246,074 | 223,400 |
| Product revenue | ||||
| Revenue: | ||||
| Total revenue | $ 43,655 | $ 30,175 | $ 78,309 | $ 58,419 |
| Cost of Revenue: | ||||
| Cost of revenue | 28,432 | 15,499 | 53,596 | 30,319 |
| Service and other revenue | ||||
| Revenue: | ||||
| Total revenue | 3,918 | 5,292 | 8,164 | 10,221 |
| Cost of Revenue: | ||||
| Cost of revenue | $ 3,412 | $ 3,592 | $ 7,204 | $ 7,607 |
PACB Balance Sheet
2023-06-30Condensed Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 209,287 | $ 325,089 |
| Investments | 620,575 | 447,229 |
| Accounts receivable, net | 24,034 | 18,786 |
| Inventory, net | 67,608 | 50,381 |
| Prepaid expenses and other current assets | 13,748 | 10,289 |
| Short-term restricted cash | 300 | 300 |
| Total current assets | 935,552 | 852,074 |
| Property and equipment, net | 40,317 | 41,580 |
| Operating lease right-of-use assets, net | 36,444 | 39,763 |
| Long-term restricted cash | 2,422 | 2,922 |
| Intangible assets, net | 409,779 | 410,245 |
| Goodwill | 409,974 | 409,974 |
| Other long-term assets | 13,143 | 10,528 |
| Total assets | 1,847,631 | 1,767,086 |
| Current liabilities | ||
| Accounts payable | 16,512 | 12,028 |
| Accrued expenses | 27,010 | 32,596 |
| Deferred revenue, current | 24,983 | 30,498 |
| Operating lease liabilities, current | 9,243 | 8,886 |
| Other liabilities, current | 7,336 | 7,233 |
| Contingent consideration liability, current | 186,325 | 172,094 |
| Total current liabilities | 271,409 | 263,335 |
| Deferred revenue, non-current | 4,992 | 1,794 |
| Operating lease liabilities, non-current | 36,599 | 41,070 |
| Convertible senior notes, net, non-current | 891,795 | 896,683 |
| Other liabilities, non-current | 837 | 1,300 |
| Total liabilities | 1,205,632 | 1,204,182 |
| Commitments and contingencies | ||
| Stockholders’ equity | ||
| Authorized 50,000 shares; No shares issued or outstanding | 0 | 0 |
| Authorized 1,000,000 shares; issued and outstanding 250,473 and 226,505 shares at June 30, 2023 and December 31, 2022, respectively | 250 | 227 |
| Additional paid-in capital | 2,334,623 | 2,099,782 |
| Accumulated other comprehensive loss | (2,686) | (4,765) |
| Accumulated deficit | (1,690,188) | (1,532,340) |
| Total stockholders’ equity | 641,999 | 562,904 |
| Total liabilities and stockholders’ equity | $ 1,847,631 | $ 1,767,086 |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.